Preclinical evaluation of drug combinations identifies co- inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma

Preclinical evaluation of drug combinations identifies co- inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma

 

Congratulations to our partners at the Institut Curie for their new paper!

You can access the full paper here